N-hydroxy-4-[[(2-oxoindol-3-yl)amino]carbamothioyl]piperazine-1-carboxamide | 1237537-66-4

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-hydroxy-4-[[(2-oxoindol-3-yl)amino]carbamothioyl]piperazine-1-carboxamide
• CAS: 1237537-66-4
• 化学式: C₁₄H₁₆N₆O₃S
• 分子量: 348.385
• InChiKey: WITZKHWGDDUHNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.07
• 重原子数：
  24.0
• 可旋转键数：
  1.0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  109.3
• 氢给体数：
  4.0
• 氢受体数：
  5.0

反应信息

• 作为产物：
  描述：

  N-hydroxypiperazine-1-carboxamide 、 3-{aza[(methylthiothioxomethyl)amino]methylene}indolin-2-one 反应 24.0h， 生成 N-hydroxy-4-[[(2-oxoindol-3-yl)amino]carbamothioyl]piperazine-1-carboxamide
  参考文献：
  名称：

  Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity

  摘要：

  Six compounds were synthesized with piperazine in linker region and hydroxamate as Zinc Binding Group ( ZBG). They were screened against three cancer cell-lines (NCIH460; HCT116; U251). Compounds 5c and 5f with GI(50) value of 9.33 +/- 1.3 mu M and 12.03 +/- 4 mu M, respectively, were tested for their inhibitory potential on hHDAC8. Compound 5c had IC(50) of 33.67 mu M. Compounds were also screened for their anticancer activity against HL60 human promyelocytic leukemia cell line due to the presence of pharmacophoric features of RR inhibitors in them. Compound 5c had IC(50) of 0.6 mu M at 48 h. (c) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.05.020

文献信息

• Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity
  作者：Bhadaliya Chetan、Mahesh Bunha、Monika Jagrat、Barij Nayan Sinha、Philipp Saiko、Geraldine Graser、Thomas Szekeres、Ganapathy Raman、Praveen Rajendran、Dhatchana Moorthy、Arijit Basu、Venkatesan Jayaprakash

  DOI：10.1016/j.bmcl.2010.05.020

  日期：2010.7

  Six compounds were synthesized with piperazine in linker region and hydroxamate as Zinc Binding Group ( ZBG). They were screened against three cancer cell-lines (NCIH460; HCT116; U251). Compounds 5c and 5f with GI(50) value of 9.33 +/- 1.3 mu M and 12.03 +/- 4 mu M, respectively, were tested for their inhibitory potential on hHDAC8. Compound 5c had IC(50) of 33.67 mu M. Compounds were also screened for their anticancer activity against HL60 human promyelocytic leukemia cell line due to the presence of pharmacophoric features of RR inhibitors in them. Compound 5c had IC(50) of 0.6 mu M at 48 h. (c) 2010 Elsevier Ltd. All rights reserved.